TerminatedNCT04532749

A Study of Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Participants With Major Depressive Disorder With Insomnia Symptoms Who Have Responded Inadequately to Antidepressant Therapy

Medication studyAges 18–74Multiple countriesDepression

The study in practice

Understand this study

Listed age limits: 18 years to 74 years.

Listed locations: Phoenix and 79 more locationsSee all locations and recruitment
Study phase: Phase 3

A point to clarify

This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?

Study clarity

Study start dateStarted: September 15, 2020

Recruitment status: Terminated
Enrollment listed in the registry: 212
Sponsor: Janssen Research & Development, LLC
Sponsor type: Other organization
Study type: Drug
Intervention type: Medication / drug
Study phase: Phase 3
Locations: United States, Argentina, Chile, ...
Age range: From 18 Years to 74 Years
Official registry ID: NCT04532749
Official title: Show the full official title
A Multicenter, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled, Study to Evaluate the Efficacy and Safety of Seltorexant 20 mg as Adjunctive Therapy to Antidepressants in Adult and Elderly Patients With Major Depressive Disorder With Insomnia Symptoms Who Have Responded Inadequately to Antidepressant Therapy

Terminated

Phoenix, United States · Little Rock, United States · Glendale, United States

61 more locations

A listed location does not confirm current availability.

FAQ

Who is behind this study?

The study sponsor is Janssen Research & Development, LLC.

Does this study involve medication?

Yes. The study involves medication, including Seltorexant and Placebo.

Who can participate?

Listed age limits: 18 years to 74 years.

Is this study still recruiting?

The registry lists this study as terminated.